KatherineALaessigMD

Infectious Disease • Washington, DC

Deputy Director, Division of Anti-infective Products, FDA

Join to view full profile

Dr. Laessig is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Laessig's full profile

Already have an account?

Office
170114th Street NW
Washington, DC 20009
Phone+1 202-745-7000

Fax+1 202-745-0238

Education & Training

George Washington UniversityFellowship, Infectious Disease, 1995 - 1997
George Washington UniversityResidency, Internal Medicine, 1992 - 1995
University of Maryland School of MedicineClass of 1992

Certifications & Licensure

MD State Medical License 1997 - 2026
VA State Medical License 1997 - 2026
DC State Medical License 1996 - 2016
American Board of Internal Medicine Infectious Disease

Publications & Presentations

PubMed

21 citations
End Points in Hospital-Acquired Pneumonia and/or Ventilator-Associated Pneumonia Clinical Trials: Food and Drug Administration Perspective
Katherine A. Laessig
Clinical Infectious Diseases. 2010-08-01
16 citations
Development of novel agents for the treatment of chronic hepatitis C infection: Summary of the FDA Antiviral Products Advisory Committee recommendations.
Kenneth E. Sherman, Russell Fleischer, Katherine A. Laessig, Jeffrey Murray, William Tauber
Hepatology. 2007-12-01
Tenofovir DF and emtricitabine vs. zidovudine and lamivudine.
Katherine A Laessig, Linda L Lewis, Thomas S Hammerstrom
The New England Journal of Medicine. 2006-06-08